Test predicts risk of blood clots in women receiving tamoxifen therapy for breast cancer

May 15, 2005

ORLANDO, Fla.--New research findings may help physicians determine which women have an increased risk of blood clots when taking tamoxifen for the management of breast cancer, a team led by Dana-Farber Cancer Institute investigators will report at the American Society of Clinical Oncology's annual meeting.

Dana-Farber's Judy Garber, MD, MPH, will present the study's data (Abstract 508) - on behalf of her colleagues at Yale University School of Medicine and more than 30 institutions and medical practices in the Cancer and Leukemia Group B consortium, a clinical research network organized by the National Cancer Institute - during an oral presentation on Sunday, May 15, at 8 a.m., Level 2, Hall A2.

The study involved more than 300 women receiving tamoxifen as "adjuvant" therapy - given after a new breast cancer diagnosis to prevent recurrence. Researchers focused on a blood-clotting protein called Factor V. Previous studies had shown that women with a specific Factor V gene mutation - which gives rise to an abnormal version of the protein, known as Factor V Leiden (FVL) - are at increased risk for blood clots when pregnant or taking oral contraceptives or estrogen replacement therapy.

In the new study, researchers found that women who had blood clots while taking tamoxifen were almost four times as likely to have an FVL mutation as were those who did not have blood clots. The results suggest that testing women in advance for FVL mutations may enable physicians to identify some women who should either use alternatives to tamoxifen or, if good alternatives are not available, use a blood thinner while taking tamoxifen.

"Other factors contributing to blood clot risk must also be considered in the decision to recommend tamoxifen to generally healthy women, including a history of previous blood clots, obesity and planned surgery," says Garber. "But FVL testing can now be used to help make this powerful medication safer for some women who need it for breast cancer treatment or prevention."
-end-
In addition to Garber, the study's other authors are Nancy Berliner, MD, Yale University School of Medicine; Susan Halabi, PhD, Duke Comprehensive Cancer Center; Ellen Kaplan, MA, CALGB Statistical Center at Duke University Medical Center; Stephen Edge, MD, Roswell Park Cancer Institute; Lynn Dressler, DrPH, UNC Lineberger Comprehensive Cancer Center; and Electra Paskett, PhD, The Ohio State University.

Dana-Farber Cancer Institute (www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.